RUSSIAN MULTICENTER EPIDEMIOLOGICAL STUDY "MEDICAL-DIAGNOSTIC TACTICS OF MANAGEMENT OF PREGNANT WOMEN WITH ARTERIAL HYPERTENSION IN RUSSIA DIALOGUE II: ANALYSIS OF RESULTS AND WAYS TO SOLVING PROBLEMS


Cite item

Full Text

Abstract

Multicenter epidemiologic DIALOGUE II study was aimed to assess the tactics of management of pregnant women with arterial hypertension (AH) and pharmacoepidemiology of antihypertensive drugs used in pregnant women in Russia in comparison with the results of DIALOGUE I study in 2005-2006. The study was conducted in 27 cities of Russia, 2033 doctors managing pregnant women with arterial hypertension were interrogated. Used terminology, diagnostic criteria, the spectrum of laboratory tests used for diagnosis and monitoring of the status of pregnant women with arterial hypertension, antihypertensive therapy during pregnancy were analyzed. The results showed that in routine clinical practice there are still no well-established diagnostic criteria and common principles for the formulation of the diagnosis of AH in pregnant women; there are no well-established criteria for the start of antihypertensive therapy. A number of necessary laboratory tests are not used adequately, 7.4% of physicians continue administrating ACE inhibitors to pregnant women, as well as other non-approved drugs, and almost 80% of physicians use drugs that are not strictly antihypertensive for the treatment of pregnant women with arterial hypertension.

References

  1. Шехтман М.М. Руководство по экстрагенитальной патологии у беременных. М., 2008. 113-48.
  2. Roberts JM, Pearson G, Cutler J, et al. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003;41:437-45.
  3. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caibbean. Brit J Obstet Gynaecol 1992;99(7):547-53.
  4. Health Canada. Special report on maternal mortality and severe morbidity in Canada - Enhanced surveillance: the path to prevention. Ottawa: Minister of Public Works and Government Services Canada; 2004.
  5. Why mothers die 2000-2002. The sixth report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press; 2004.
  6. Серов В.Н., Фролова О.Г., Токова З.З. Основные причины материнской смертности в последние 5 лет // Проблемы беременности. 2001. .№ 3. C. 15-9.
  7. Rodie VA, Freeman DJ, Sattar N, et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004;175(2):189-202.
  8. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:159-67.
  9. Макаров О.В., Николаев Н.Н., Волкова Е.В. и соавт. Тактика ведения беременных с различными формами артериальной гипертензии. Материалы 8-го Всероссийского научного форума "Мать и дитя" 2006. С. 149.
  10. Сидорова И.С. Гестоз. М., 2003. С. 41.
  11. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:1-22.
  12. Podymow Т, August Ph. Update on the Use of Antihypertensive Drugs in Pregnancy. Hypertension 2008;51:960-9.
  13. Lowe SA, Brown MA, Dekker G, et al. Guidelines for the management of hypertensive disorders of pregnancy. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) 2009;49(3):242-6.
  14. Diagnostik und therapie hypertensiver schwangerschaftserkrankungen Deutsche Gesellschaft furGynakologie und Geburtshilfe (DGGG), Arbeitsgemeinschaft Schwangerschaftshochdruck / Gestose 2008;24.
  15. Hypertension Guideline Committee and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. J Obstet Gynaecol Can 2008;30(3):1-48.
  16. Рабочая группа по лечению артериальной гипертонии Европейского общества гипертонии (ESH) и Европейского общества кардиологов (ESC) Рекомендации 2007 года по лечению артериальной гипертонии // Рациональная Фармакотерапия в Кардиологии 2008. № 1-2. C. 51-3.
  17. ESC Expert Consensus Document on Management of Cardiovascular Diseases during Pregnancy. European Heart Journal 2003;24(8):761-81.
  18. North RA, Taylor RS, Schellenberg JC. Evaluation of a definition of pre-eclampsia. Br J Obstet Gynaecol 1999;106:767-73.
  19. Levine RJ, Ewell MG, Hauth JC, et al. Should the definition of preeclampsia include a rise in diastolic blood pressure of >/=15 mm Hg to a level Am J Obstet Gynecol 2000;183(4):787-92.
  20. Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005;105:246-54.
  21. Helewa M, Heaman M, Robinson MA, et al. Community-based home-care program for the management of pre-eclampsia: an alternative. CMAJ 1993;149:829-34.
  22. Abalos E, Duley L, Steyn D, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007;24(1):CD002252.
  23. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999;318:1332-6.
  24. Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355:87-92.
  25. Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002;24(12):941-5.
  26. Magee LA, von Dadelszen P, Chan S, et al. The CHIPS Pilot Trial (Control of Hypertension In Pregnancy Study). J Obstet Gynaecol Can 2006;28:416.
  27. Макаров О.В., Николаев Н.Н., Волкова Е.В. и соавт. Параметры центральной гемодинамики в дифференциальной диагностике различных форм артериальной гипертензии у беременных. Материалы 8-го Всероссийского научного форума "Мать и дитя" 2006. 149.
  28. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1:647-9.
  29. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174:823-8.
  30. Bortolus R, Ricci E, Chatenoud L, et al. Nifedipine administered in pregnancy: effect on the development of children at 18 months. Br J Obstet Gynaecol 2000;107:792-4.
  31. Серов В.Н. Гестоз: современная лечебная тактика // Фарматека. 2004. № 1. C. 67-71.
  32. Макаров О.В., Николаев Н.Н., Волкова Е.В. Артериальная гипертензия у беременных. Только ли гестоз? М., 2006. С. 174.
  33. Groves TD, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol 1995;172:1655-6.
  34. Kisters K, et al. Membrane, intracellular, and plasma magnesium and calcium concentrations in preeclampsia Am J Hypertens 2000;13(7):765-9.
  35. Qi Q, et al. Magnesium and calcium concentrations of peripheral serum and mononuclear cells in patients with pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi 1997;32(1):15-8.
  36. Li S, Tian H. Oral low-dose magnesium gluconate preventing pregnancy induced hypertension. 1997 Zhonghua Fu Chan Ke Za Zhi 1997;32(10):613-5.
  37. Верткин А.Л., Ткачева О.Н., Мурашко Л.Е. и соавт. Обмен магния и терапия препаратами магния при гестозе // Акушерство, Гинекология, Педиатрия. 2005. № 2. C. 98.
  38. Верткин А.Л., Ткачева О.Н., Ткачева О.М. и соавт. Некоторые аспекты применения препаратов магния при беременности // Проблемы репродукции. 2005;.№ 4. C. 57-63.
  39. Makrides M, Crowther CA. Magnesium supplementation in pregnancy. Cochrane Database Syst Rev 2001;(4):CD000937.
  40. Hanssens M, Keirse MJ, Vankelecom F, et al. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991;78:128-35.
  41. Buttar HS. An overview of the influence of ACE inhibitors on fetal placental circulation and perinatal development. Mol Cell Biol 1997;176:61-71.
  42. Saji H, Yamanaka M, Hagiwara A, et al. Losartan and fetal toxic effects. Lancet 2001;357:363.
  43. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. JAMA 1997;277:1193-4.
  44. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001;35:859-61.
  45. Lambot MA, Vermeylen D, Noel JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1619-20.
  46. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-51.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies